Haizheng pharmaceutical: "acarbose tablet" new 100mg specification application approved

IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives

In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow

Bonitas Research Shorts Huazhu Hotel, Claiming It Inflated Profits

The report was released on the company's first day of trading on HKEX.

Huazhu's Second Quarter Report: Revenue Falls by 32% While Losses Narrow

Ji Qi, the founder and executive chairman of Huazhu, claims that, in the next three years, Huazhu will focus more on ' penetration of lower-tier cities.

Huazhu's Second Listing in Hong Kong Nears

Huazhu's second listing in Hong Kong is as soon as in September.

Huazhu Group Suffers Losses of CNY 2.1 Billion

It is expected that the company’s net revenue in the second quarter will decline by 32% to 34% YoY.